GSK signs deal with Fiocruz for dengue fever
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline is reinforcing its efforts into tackling diseases pre-eminent in the developing economies by enhancing its existing relationship with the Rio de Janeiro-based Oswaldo Cruz Foundation (Fiocruz). The UK multinational, which already has links with Fiocruz, is expanding the coverage of their relationship to include Chagas disease and lieshmanioses initially, but also malaria and tuberculosis.